Dexcom (DXCM) Long-Term Deferred Tax (2020 - 2026)

Dexcom (DXCM) has 7 years of Long-Term Deferred Tax data on file, last reported at $296.1 million in Q1 2026.

• Quarterly Long-Term Deferred Tax fell 39.24% year-over-year to $296.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $296.1 million (down 39.24% YoY) and the FY2025 annual result came in at $295.6 million, down 38.57% from the prior year.
• Long-Term Deferred Tax held at $296.1 million in Q1 2026 per DXCM's latest filing, from $295.6 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $501.3 million in Q3 2023 and bottomed at $290.8 million in Q1 2022.
• The 5-year median for Long-Term Deferred Tax is $417.0 million (2023), against an average of $401.5 million.
• The widest annual swing landed in 2022, when Long-Term Deferred Tax surged 58.25%; it then plunged 39.24% in 2026.
• Tracing DXCM's Long-Term Deferred Tax over 5 years: stood at $341.2 million in 2022, then advanced by 22.92% to $419.4 million in 2023, then gained by 14.74% to $481.2 million in 2024, then tumbled by 38.57% to $295.6 million in 2025, then advanced by 0.17% to $296.1 million in 2026.
• Per Business Quant, the three latest DXCM Long-Term Deferred Tax figures stand at $296.1 million (Q1 2026), $295.6 million (Q4 2025), and $375.6 million (Q3 2025).

Peer Comparison